Distillate Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Distillate Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,252	Closed	-$7.38M	–	169
2022 Q3	$7.38M	Sell	25,252 -4,373	-15%	-$1.26M	0.99%	30
2022 Q2	$8.35M	Sell	29,625 -755	-2%	-$202K	1.19%	17
2022 Q1	$7.93M	Buy	30,380 +4,652	+18%	+$1.1M	1.13%	23
2021 Q4	$5.65M	Buy	25,728 +8,782	+52%	+$1.71M	0.95%	32
2021 Q3	$3.07M	Buy	+16,946	New	+$3.31M	0.82%	57

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Distillate Capital Partners's VRTX Position: Q4 2022 in Review

Distillate Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 25,252 shares — an estimated $7.38M sold.

Distillate Capital Partners first reported a position in VRTX in Q3 2021 and held it in 5 quarters. The position peaked at $8.35M in Q2 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Distillate Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Distillate Capital Partners sold 25,252 Vertex Pharmaceuticals shares in Q4 2022, an estimated $7.38M.
Distillate Capital Partners first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Distillate Capital Partners's Vertex Pharmaceuticals position peaked at $8.35M in Q2 2022.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Distillate Capital Partners's 13F filing for Q4 2022, filed 15 Feb 2023.